Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation

The Thrombopoietin Receptor (TpoR) is a central player in Myeloproliferative Neoplasms (MPNs). Mutations in JAK2, calreticulin or in TpoR itself drive constitutive activation of TpoR and uncontrolled proliferation and differentiation of hematopoietic stem cells and progenitors. The JAK2 V617F mutati...

Full description

Bibliographic Details
Main Authors: Papadopoulos, N, Pristavec, A, Nédélec, A, Levy, G, Staerk, J, Constantinescu, SN
Format: Journal article
Language:English
Published: American Society of Hematology 2023
_version_ 1811141049176817664
author Papadopoulos, N
Pristavec, A
Nédélec, A
Levy, G
Staerk, J
Constantinescu, SN
author_facet Papadopoulos, N
Pristavec, A
Nédélec, A
Levy, G
Staerk, J
Constantinescu, SN
author_sort Papadopoulos, N
collection OXFORD
description The Thrombopoietin Receptor (TpoR) is a central player in Myeloproliferative Neoplasms (MPNs). Mutations in JAK2, calreticulin or in TpoR itself drive constitutive activation of TpoR and uncontrolled proliferation and differentiation of hematopoietic stem cells and progenitors. The JAK2 V617F mutation is responsible for the majority of MPNs and all driver mutants induce pathologic TpoR activation. Existing therapeutic strategies have focused on JAK2 kinase inhibitors that are unable to differentiate between the mutated MPN clone and healthy cells. Surprisingly, targeting of TpoR itself has remained poorly explored despite its central role in the pathology. Here, we performed a comprehensive characterization of human TpoR activation in physiological and pathological conditions focusing on the JAK2 V617F mutant. Using a system of controlled dimerization of transmembrane and cytosolic domains of TpoR, we discovered that the human TpoR (hTpoR) adopts different dimeric conformations upon Tpo-induced versus JAK2 V617F-mediated activation. We identified the amino acids and the specific dimeric conformation of hTpoR responsible for activation in complex with JAK2 V617F and confirmed our findings in the full-length receptor context in hematopoietic cell lines and primary bone marrow cells. Remarkably, we find that modulation of hTpoR conformations by point mutations allows specific inhibition of the JAK2 V617F-driven activation without affecting Tpo-induced signaling. Our results demonstrate that modulation of hTpoR conformation is a viable therapeutic strategy for JAK2 V617F positive MPNs and set the path for novel drug development by identifying precise residues of hTpoR involved in JAK2 V617F specific activation.
first_indexed 2024-03-07T08:06:24Z
format Journal article
id oxford-uuid:4f577cc8-9b19-4669-8fbb-19d1dd29dc5b
institution University of Oxford
language English
last_indexed 2024-09-25T04:31:41Z
publishDate 2023
publisher American Society of Hematology
record_format dspace
spelling oxford-uuid:4f577cc8-9b19-4669-8fbb-19d1dd29dc5b2024-08-29T09:25:42ZModulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4f577cc8-9b19-4669-8fbb-19d1dd29dc5bEnglishSymplectic ElementsAmerican Society of Hematology2023Papadopoulos, NPristavec, ANédélec, ALevy, GStaerk, JConstantinescu, SNThe Thrombopoietin Receptor (TpoR) is a central player in Myeloproliferative Neoplasms (MPNs). Mutations in JAK2, calreticulin or in TpoR itself drive constitutive activation of TpoR and uncontrolled proliferation and differentiation of hematopoietic stem cells and progenitors. The JAK2 V617F mutation is responsible for the majority of MPNs and all driver mutants induce pathologic TpoR activation. Existing therapeutic strategies have focused on JAK2 kinase inhibitors that are unable to differentiate between the mutated MPN clone and healthy cells. Surprisingly, targeting of TpoR itself has remained poorly explored despite its central role in the pathology. Here, we performed a comprehensive characterization of human TpoR activation in physiological and pathological conditions focusing on the JAK2 V617F mutant. Using a system of controlled dimerization of transmembrane and cytosolic domains of TpoR, we discovered that the human TpoR (hTpoR) adopts different dimeric conformations upon Tpo-induced versus JAK2 V617F-mediated activation. We identified the amino acids and the specific dimeric conformation of hTpoR responsible for activation in complex with JAK2 V617F and confirmed our findings in the full-length receptor context in hematopoietic cell lines and primary bone marrow cells. Remarkably, we find that modulation of hTpoR conformations by point mutations allows specific inhibition of the JAK2 V617F-driven activation without affecting Tpo-induced signaling. Our results demonstrate that modulation of hTpoR conformation is a viable therapeutic strategy for JAK2 V617F positive MPNs and set the path for novel drug development by identifying precise residues of hTpoR involved in JAK2 V617F specific activation.
spellingShingle Papadopoulos, N
Pristavec, A
Nédélec, A
Levy, G
Staerk, J
Constantinescu, SN
Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation
title Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation
title_full Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation
title_fullStr Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation
title_full_unstemmed Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation
title_short Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven from cytokine-induced activation
title_sort modulation of human thrombopoietin receptor conformations uncouples jak2 v617f driven from cytokine induced activation
work_keys_str_mv AT papadopoulosn modulationofhumanthrombopoietinreceptorconformationsuncouplesjak2v617fdrivenfromcytokineinducedactivation
AT pristaveca modulationofhumanthrombopoietinreceptorconformationsuncouplesjak2v617fdrivenfromcytokineinducedactivation
AT nedeleca modulationofhumanthrombopoietinreceptorconformationsuncouplesjak2v617fdrivenfromcytokineinducedactivation
AT levyg modulationofhumanthrombopoietinreceptorconformationsuncouplesjak2v617fdrivenfromcytokineinducedactivation
AT staerkj modulationofhumanthrombopoietinreceptorconformationsuncouplesjak2v617fdrivenfromcytokineinducedactivation
AT constantinescusn modulationofhumanthrombopoietinreceptorconformationsuncouplesjak2v617fdrivenfromcytokineinducedactivation